Cantor Fitzgerald Raises Apellis Pharmaceuticals (APLS) Price Target to $53.00

Retrieved on: 2018-09-01 04:26:15

Tags for this article:

Biotechnology

Industries

Life Sciences

Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc.

Price–earnings ratio

Click the tags to see associated articles and topics

Cantor Fitzgerald Raises Apellis Pharmaceuticals (APLS) Price Target to $53.00. View article details on hiswai:

Excerpt

<div><b>Sofinnova Ventures</b> Inc acquired a new stake in Apellis Pharmaceuticals in the 1st quarter worth about $20,159,000. Geode Capital Management LLC ...</div>

Article found on:

View Original Article